JUPITER data justify statin use against diabetes concerns
This article was originally published in Scrip
Executive Summary
Concerns over statin use increasing the risk of developing diabetes should not prevent their use even in patients at high risk of developing the metabolic disease, suggests a new analysis of the JUPITER study of AstraZeneca's Crestor (rosuvastatin). The cardiovascular and mortality benefits of statin therapy exceed the diabetes hazard, the researchers found, allaying fears over their use, particularly in primary prevention.